WORCESTER, Mass., Jan. 23, 2008 (PRIME NEWSWIRE) -- Generex Biotechnology Corporation (Nasdaq:GNBT), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, announced that on January 22, 2008 the Ministry of Health of the Ukraine issued an approval letter for the conduct of a Phase III clinical trial protocol for Generex Oral-lyn(tm) at eight clinical sites located in the Ukraine. The significance of this approval is that it represents initiation of the first clinical sites for the pivotal study and permits commencement of screening for suitable patients. This approval is the first of seven countries within which the Company will be conducting the Phase III trial of Generex Oral-lyn.
